Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors.
Wang Z, Zheng M, Li M, Lu H, Liu N, Chen Y, Yang N, Zeng W, Dong Y, Li J, Zhu Z, Yang C, Zhang Z, Lu Q, Li H, Zhou L, Yang H, Tong A.
Wang Z, et al. Among authors: zhu z.
Mol Cancer Ther. 2024 Nov 27. doi: 10.1158/1535-7163.MCT-24-0319. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 39600127